Immuno-oncology – The Breakthrough in Cancer Therapeutics Cancer immuno-oncology (IO) uses the body’s natural defenses to combat cancer. These therapies stimulate an individual’s immune system and restore its ability to identify and destroy cancer cells. Anti-cancer immune responses are often inhibited during the spread of cancer. Ultimately, IO therapy expedites long term responses against cancer […]Read More
Author: Piet van der Graaf and Andrzej Kierzek
Andrzej Kierzek graduated with an undergraduate degree in molecular biology from the University of Warsaw and received a PhD in biophysics from Polish Academy of Sciences in 1999. Since 2004, he has been working at University of Surrey, UK and became Professor of Systems Biology in 2011. In April 2016, he moved to Certara QSP as Head of Systems Modeling. He is still a visiting Professor of Systems Biology at Surrey. Andrzej has more than 20 years of experience in computational biology. He has been working in computational systems biology for over 15 years. He published models and software for analysis of molecular network dynamics and constraint-based modeling of genome scale metabolic networks, including metabolic reprogramming in cancer. Currently, his research focus is on immune-oncology and immunogenicity. Piet has 15 years’ experience working in the pharmaceutical industry at Synthélabo (Sanofi) and Pfizer, where he held leadership positions in Discovery Biology, Pharmacokinetics & Drug Metabolism (PDM) and Clinical Pharmacology/Pharmacometrics. He obtained his PharmD from the University of Groningen, The Netherlands, and a PhD in quantitative pharmacology from King’s College London, UK, and was elected as a Fellow of the British Pharmacological Society. He is also Editor-in-Chief of CPT: Pharmacometrics & Systems Pharmacology. He brings his considerable skill and experience to our projects and contributes to the strategic development of Certara.